Trial
NCT02437162
A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis
Phase IIITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Janssen Research & Development, LLC
Collaborators
—
Condition
Axial Spondyloarthritis
Intervention
Placebo
Why stopped
Neither dose achieved the study's primary or major secondary endpoints. The safety profile was consistent with previous ustekinumab studies.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-04-29